Azithromycin in older people with airway disease

A double-blind randomised controlled study of the anti-inflammatory effects of azithromycin 250mg daily for 12 weeks in adults with symptomatic neutrophilic airway disease

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12609000259246

Acronym

MAZDA

Enrollment

Registered

2009-05-13

Start date

2009-06-16

Completion date

2010-11-23

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The primary purpose of the study is to further the identification of effective treatment options for people with obstructive airway diseases, such as asthma and chronic obstructive pulmonary disease, and neutrophilic inflammation. The study will investigate the anti-inflammatory effect of a macrolide antibiotic, azithromycin, on airway inflammation, symptoms, quality of life and lung function. It is hypothesised that azithromycin therapy will reduce bacteria in the sputum and inflammatory cells of participants with neutrophilic airway disease.

Interventions

Azithromycin 250mg daily for 12 weeks, by oral administration.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used) (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

All

Age

55 Years to No maximum

Healthy volunteers

Inclusion criteria

Symptomatic stable asthma or Chronic Obstructive Pulmonary Disease (COPD), increased sputum neutrophils.

Exclusion criteria

Hypersensitivity to macrolides, other respiratory disease, taking macrolide, tetracycline, antibiotic or oral corticosteroid in past month, taking antacid treatment, taking medication that prolongs the heart's corrected QT interval (QTc), current smoking, pregnancy, impaired liver function.

Outcome results